Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

DEN SELVEJENDE INSTITUTION BIO-HUSET FOND Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 2.8% 2.8%   Bankruptcy risk   3.5% 2.7% 2.3% 5.6% 2.8% 3.5% 10.6% 10.3%   Credit score (0-100)   54 61 64 39 59 52 23 24   Credit rating   BBB BBB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   514 561 486 237 619 389 0.0 0.0   EBITDA   120 170 108 -83.2 226 90.1 0.0 0.0   EBIT   84.3 142 70.6 -135 183 57.6 0.0 0.0   Pre-tax profit (PTP)   84.7 140.2 62.5 -144.1 171.9 56.9 0.0 0.0   Net earnings   84.7 118.8 62.4 -144.1 171.9 56.9 0.0 0.0   Pre-tax profit without non-rec. items   84.7 140 62.5 -144 172 56.9 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   62.3 67.5 317 265 253 2,565 0.0 0.0   Shareholders equity total   1,222 1,340 1,403 1,260 1,522 1,579 1,187 1,187   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,371 1,509 1,533 1,699 2,381 4,781 1,187 1,187   Net Debt   -1,231 -1,344 -1,093 -1,304 -2,025 -1,711 -1,187 -1,187     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   514 561 486 237 619 389 0.0 0.0   Gross profit growth   3.3% 9.1% -13.3% -51.4% 161.7% -37.2% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,371 1,509 1,533 1,699 2,381 4,781 1,187 1,187   Balance sheet change%   8.2% 10.1% 1.6% 10.8% 40.1% 100.8% -75.2% 0.0%   Added value   119.5 170.0 108.0 -83.2 235.2 90.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -35 -23 212 -104 -55 2,279 -2,565 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 -1.0 1.0 2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   16.4% 25.3% 14.5% -57.2% 29.6% 14.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   6.5% 9.9% 4.6% -8.4% 9.0% 1.6% 0.0% 0.0%   ROI %   7.3% 11.1% 5.1% -10.2% 13.2% 3.8% 0.0% 0.0%   ROE %   7.2% 9.3% 4.6% -10.8% 12.4% 3.7% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   90.2% 92.0% 96.6% 81.7% 68.4% 34.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -1,030.1% -790.3% -1,011.8% 1,566.3% -895.7% -1,899.3% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   9.6 12.3 24.3 4.9 3.0 0.7 0.0 0.0   Current Ratio   8.8 8.5 9.3 3.3 2.5 0.7 0.0 0.0   Cash and cash equivalent   1,231.4 1,343.5 1,092.7 1,303.8 2,024.7 1,711.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,159.3 1,272.9 1,085.6 995.2 1,268.9 -985.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   120 170 108 -83 235 90 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   120 170 108 -83 226 90 0 0   EBIT / employee   84 142 71 -135 183 58 0 0   Net earnings / employee   85 119 62 -144 172 57 0 0